ABSTRACT
We explored the impact of the Spanish COVID-19 strict home confinement on mental health and cognition in non-infected subjects (Nâ=â16, 60-80 years) diagnosed with subjective cognitive decline and APOEÉ3/É4 carriers. Mental health was monitored for 2 months on a daily, weekly, or monthly basis, and compared to pre-confinement values. Emotional distress, anxiety, and depression scores increased to pathological threshold values during and after confinement. Those with lower mood during confinement experienced a decline in their mood after confinement. Cognition did not change. These preliminary results suggest that mental health consequences of corona measures in preclinical stages of Alzheimer's disease should be further evaluated.
Subject(s)
Alzheimer Disease/psychology , COVID-19/psychology , Cognition Disorders/psychology , Mental Health , Quarantine/psychology , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/genetics , Anxiety Disorders/diagnosis , Anxiety Disorders/genetics , Anxiety Disorders/psychology , Apolipoprotein E3/genetics , Apolipoprotein E4/genetics , COVID-19/genetics , COVID-19/therapy , Cognition Disorders/diagnosis , Cognition Disorders/genetics , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/genetics , Cognitive Dysfunction/psychology , Depressive Disorder/diagnosis , Depressive Disorder/genetics , Depressive Disorder/psychology , Female , Humans , Male , Middle Aged , Psychological Distress , Risk , SpainABSTRACT
Antecedentes y objetivo: Una de las limitaciones del SCORE es que no permite calcular el riesgo en mayores de 65 años. Recientemente, los investigadores del SCORE han publicado unas tablas específicas para mayores (SCORE Older Persons [SCORE OP]). El objetivo del presente estudio fue evaluar el impacto de la utilización de las tablas SCORE OP en una población española de pacientes mayores de 64 años y su comparación con las tablas SCORE en el grupo entre 65 y 69 años. Pacientes y método: Estudio transversal realizado en 2 centros de salud urbanos. Se seleccionaron individuos de entre 65 y 85 años sin antecedentes de diabetes mellitus o enfermedad cardiovascular. Se calculó el riesgo utilizando las tablas para países de bajo riesgo SCORE y las nuevas OP. Resultados: Se calculó el riesgo cardiovascular a 3.425 pacientes. En el grupo de entre 65-69 años (n = 974, 22,44%) la media de riesgo según el SCORE fue de 4,08, y según el SCORE OP, de 3,83 (p < 0,001). El porcentaje de pacientes de riesgo alto fue de un 25,46% con SCORE y de 22,90% con SCORE OP (p < 0,001). Utilizando el SCORE deberíamos tratar con hipolipidemiantes al 16,43% de los pacientes, mientras que con el SCORE OP deberíamos tratar al 13,45%. Utilizando SCORE OP en pacientes mayores de 69 años deberíamos tratar con hipolipidemiantes al 61,49% de los pacientes. Conclusiones: Las tablas SCORE OP para mayores de 64 años identifican menos pacientes de alto riesgo que las tablas SCORE, lo que implicaría tratar potencialmente menos pacientes de esas edades con hipolipidemiantes (AU)
Background and objective: Estimating cardiovascular risk with SCORE is not recommended in persons over 65 years. SCORE investigators have recently published specific tables for older people (SCORE Older Persons [SCORE OP]). The aim of this study is to assess the impact of using SCORE OP tables on a Spanish population aged over 64 years, and compare it with the use of SCORE in patients aged 65-69 years. Patients and method: Cross-sectional study carried out in 2 urban primary health care centres. Individuals between 65 and 85 years old without diabetes or established cardiovascular diseases were included. Cardiovascular risk using SCORE and the new SCORE OP tables for low risk countries was calculated. Results: Cardiovascular risk was estimated in 3,425 patients. Mean values of the original SCORE and SCORE OP were 4.08 and 3.83, respectively in the group of patients aged 65-69 years old (n = 974, 22.44%) (P < .001). The percentage of patients at high or very high risk was 25.46% and 22.90% with the original SCORE and the SCORE OP, respectively (P < .001). Using the original SCORE, 16.43% of the total patients should potentially be treated with lipid lowering drugs, while using the SCORE OP, 13.45% of the patients aged 65-69 years should potentially be treated. Using SCORE OP in patients older than 69 years, 61.49% patients should potentially be treated with lipid lowering drugs. Conclusions: SCORE OP identifies fewer patients at high or very high risk than the original SCORE, therefore, its utilization would imply treating fewer patients of this age with lipid lowering drugs (AU)
Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Cardiovascular Diseases/prevention & control , Health Status Indicators , Age Factors , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/etiology , Cross-Sectional Studies , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Risk Assessment , Risk Factors , Retrospective StudiesABSTRACT
No disponible
Subject(s)
Humans , Cardiovascular Diseases/prevention & control , Risk Adjustment/methods , Risk Factors , Practice Patterns, Physicians'ABSTRACT
BACKGROUND AND OBJECTIVE: Estimating cardiovascular risk with SCORE is not recommended in persons over 65 years. SCORE investigators have recently published specific tables for older people (SCORE Older Persons [SCORE OP]). The aim of this study is to assess the impact of using SCORE OP tables on a Spanish population aged over 64 years, and compare it with the use of SCORE in patients aged 65-69 years. PATIENTS AND METHOD: Cross-sectional study carried out in 2 urban primary health care centres. Individuals between 65 and 85 years old without diabetes or established cardiovascular diseases were included. Cardiovascular risk using SCORE and the new SCORE OP tables for low risk countries was calculated. RESULTS: Cardiovascular risk was estimated in 3,425 patients. Mean values of the original SCORE and SCORE OP were 4.08 and 3.83, respectively in the group of patients aged 65-69 years old (n=974, 22.44%) (P< .001). The percentage of patients at high or very high risk was 25.46% and 22.90% with the original SCORE and the SCORE OP, respectively (P<.001). Using the original SCORE, 16.43% of the total patients should potentially be treated with lipid lowering drugs, while using the SCORE OP, 13.45% of the patients aged 65-69 years should potentially be treated. Using SCORE OP in patients older than 69 years, 61.49% patients should potentially be treated with lipid lowering drugs. CONCLUSIONS: SCORE OP identifies fewer patients at high or very high risk than the original SCORE, therefore, its utilization would imply treating fewer patients of this age with lipid lowering drugs.
